BridgeBio price target raised to $57 from $55 at Scotiabank

Scotiabank raised the firm’s price target on BridgeBio (BBIO) to $57 from $55 and keeps an Outperform rating on the shares. The firm continues to be impressed by the company’s early commercial momentum and raises it price target on the stock to reflect updated Attruby sales expectations, the analyst tells investors.